Collectively, these studies indicate that PD-1 or PD-L1 inhibitors generally exhibit limited efficacy in pediatric patients with non-lymphoma malignancies, which may be attributed to factors such as low tumor mutational burden or negative PD-L1 expression in the tumor microenvironment. The gene discussed is CD274; the disease is lymphoma.